BioSpace News Archive

Polyclonal antibodies are potentially powerful tools in a wide range of biomedical and biochemical research, world over.

Thousands of deaths are occurring on a yearly basis on account of various viral infectious diseases. Some of the viral diseases occurring are rabies, avian influenza, HIV-1, measles, enterovirus, poliovirus, coronavirus, and Metapneumovirus.

Arch Therapeutics, Inc. announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $6.9 million through the issuance of an aggregate 43,125,002 shares of its common stock and warrants to purchase up to an aggregate of 32,343,751 shares of common stock, at a combined purchase price of $0.16 per share of common stock and associated warrant in a private placement.

Faricimab showed rapid and consistent improvements in anatomical outcomes including central subfield thickness across all studies

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, announces that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for LYS-GM101, the company’s gene therapy candidate for the treatment of GM1 gangliosidosis, a serious, pediatric, life threatening disease.

New results from the PXL770 Phase 2a STAMP-NAFLD trial for the treatment of NASH showed consistently greater response in high-risk patients with coexisting type 2 diabetes (T2DM), which is estimated to affect approximately 50% of NASH patients

Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring action (pending a site inspection) on the Stratatech Biologics License Application (BLA) for StrataGraft ® , an investigational allogeneic cellularized scaffold product

SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the pricing of its underwritten public offering of 3,000,000 shares of common stock at a public offering price of $20.00 per share.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021.

Sensient Technologies Corporation (NYSE: SXT) reported consolidated revenue of $334.7 million in this year’s fourth quarter